Opioid crisis response expanded: $1B+ in new federal funding through 2030

What it does

This bill reauthorizes and expands federal programs addressing opioid use disorder, substance misuse, and related mental health crises through 2030. It increases funding for prevention (prenatal health, overdose detection, fentanyl awareness), treatment (addiction medicine, residential programs for pregnant women, loan repayment for treatment workers), and recovery (peer support, community recovery centers, job training). It also establishes new initiatives on cybersecurity for the suicide prevention lifeline, fetal alcohol spectrum disorder services, and health IT adoption in mental health settings.

Why we flagged it

The bill's operative mechanism is straightforward: it reauthorizes and increases appropriations for existing federal substance use disorder and mental health programs administered by HHS/SAMHSA. No deregulation, no liability shields, no tax carve-outs—purely programmatic expansion.

What the text implies

• Section 105 (PDMP state choice) constrains federal authority to mandate specific vendors or interoperability standards beyond 'nationally recognized, consensus-based open standards'—may reduce federal leverage over state prescription drug monitoring systems.
• Section 209 (buprenorphine/naloxone scheduling review) delegates to Attorney General whether to initiate rulemaking; no mandate to act, creating discretionary gate on potential rescheduling that could expand access.
• Section 211 (health IT roundtable) is advisory only—no binding requirement to adopt recommendations, limiting concrete impact on EHR adoption in mental health/SUD settings despite documented barriers.
• Section 302(d) (regional peer support centers) is pilot-only, terminates Sept 30, 2030, and uses 'existing resources'—no new dedicated funding, limiting scalability.
• Multiple sections require reports/studies (Comptroller General cybersecurity study, FDA opioid assessment, state guidance review) but do not mandate regulatory action, creating information-gathering without enforcement teeth.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands public health infrastructure for opioid prevention, treatment, and recovery—areas with documented public health crisis. Funding increases flow to state/tribal/local entities and nonprofits delivering services to vulnerable populations (pregnant women, youth, individuals with substance use disorders). No provisions restrict citizen rights or create private liability shields.

Who stands to gain

• State and Tribal health agencies (grant recipients)
• Nonprofit organizations providing substance use disorder and mental health services
• Academic and research institutions (FASD research, NCTSI grantees)
• Local government and community-based organizations
• Health IT vendors (indirectly, via EHR adoption incentives in roundtable recommendations)

Named in the bill

HHS/SAMHSA, FDA, DEA, CDC, State health departments, Indian Tribes and Tribal organizations, Substance Abuse and Mental Health Services Administration, National Coordinator for Health Information Technology, Comptroller General, Attorney General

Where it stands

1 cosponsor: 1 Democrats.

• Mar 31, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 31, 2025 — Referred to House Committee on Financial Services and House Committee on the Judiciary · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and…”
• Apr 29, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Apr 29, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 36 - 13”
• Jun 4, 2025 — Passed the House · Congress.gov: “On passage Passed by the Yeas and Nays: 366 - 57 (Roll no. 151)”
• Sep 18, 2025 — Passed both chambers · Congress.gov: “Passed Senate without amendment by Unanimous Consent. (consideration: CR S6712)”
• Nov 25, 2025 — Sent to president · Congress.gov: “Presented to President”
• Dec 1, 2025 — Signed into law · Congress.gov: “Became Public Law No: 119-44”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

27 lobbying clients named this bill on 40 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $16,624,162 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Brett Guthrie, the sponsor, reported $3,193,402 in PAC receipts in the 2026 cycle. $13,000 of that came from 2 PACs tied to these lobbying clients.

• American Medical Association — $5,643,000 on 2 filings
• American Optometric Association — $2,350,000 on 2 filings
• American Academy of Family Physicians — $1,715,904 on 2 filings
• Blue Cross and Blue Shield Association — $1,440,000 on 1 filing
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.